In 2006 when Orphan Drug Solutions first went to Viropharma’s offices (prior to them being acquired by Shire), they had 80 employees dedicated to the advancement of their primary drug, Cinryze. Cinryze was and is the only FDA-approved C1 esterase inhibitor therapy used to treat HAE (Hereditary Angioedema), so its success was not just important for them as a company, …
Life Sciences Future 2014
Last week, the ODS team and I packed up our car and headed out to Philadelphia for PA Bio’s “Life Sciences Future” event! Not only did we get to listen to some of the brightest influencers in the industry talk about what they’re doing, but we also had an exhibit table, and were able to show off our flagship product to …